CN104546937B - Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease - Google Patents
Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease Download PDFInfo
- Publication number
- CN104546937B CN104546937B CN201410524063.7A CN201410524063A CN104546937B CN 104546937 B CN104546937 B CN 104546937B CN 201410524063 A CN201410524063 A CN 201410524063A CN 104546937 B CN104546937 B CN 104546937B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- clostridium nexile
- clostridium
- nexile
- rheumatoid arthritis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides Clostridium nexiles to treat or prevent the purposes in rheumatoid arthritis or its related disease, additionally provides the pharmaceutical composition comprising Clostridium nexile, drug, food and feed.By giving animal to provide Clostridium nexile, anti-inflammatory effect can be effectively played, the symptom of joint redness and swelling is effectively improved, and arthritic symptom is substantially reduced, can be effective for treating or preventing rheumatoid arthritis or its related disease.
Description
Technical field
The present invention relates to microbiological arts, and in particular, to Clostridium nexile is treating or preventing rheumatoid arthritis
Or the purposes in its related disease, also it is related to pharmaceutical composition, drug, food and feed comprising Clostridium nexile.
Background technique
Rheumatoid arthritis (rheumatoid arthritis, RA) abbreviation rheumatoid, which is that one kind is systemic, itself to be exempted from
Epidemic disease disease, mainly involves synovium of joint, is secondly the connective tissues such as serous coat, the heart, lung, blood vessel, nerve.Acute phase inflammatory is main
Synovial membrane angioedema, synovitis are shown as, if acute inflammatory reaction subsides, and exudation gradually absorbs not by timely diagnosing and treating,
Synovial membrane medium vessels screen is formed, the significant hyperplasia of synovial cell.Then cause articular cartilage damage, bone tissue inflammation, necrosis and fiber
Connective tissue proliferation.Calcification then occurs and fibroid and bone arthrosclerosis occurs, articular cavity is significant narrow or completely disappears.This
Joint function disturbance caused by phase chronic inflammation processes is largely difficult to restore, can lead to permanent disability.The whole world is every
Just there is 1 people with RA in 100~150 people, China's illness rate is 0.32%~0.36%.RA can all fall ill at each age, adult
In be mainly in female middle-aged, the ratio between men and women about 1:3.2003 according to WHO, under good medical condition, for each person every year
Medical expense is about 6000 dollars, and the indirect loss as caused by the disease also can not be ignored.
Currently, doctor trained in Western medicine mainly uses the methods of drug therapy and gene therapy.Common Western medicine mainly has non-steroidal anti-inflammatory drugs
(NSAIDs), glucocorticoid, make medication, immunosuppressor and biological agent slowly etc..But Western medicine generally has, and price is high, poison is secondary
Larger disadvantage is acted on, so limiting their application.The selectivity of gene therapy is high, can be directed to disease from molecular level
It is treated, while new way can be opened for the treatment of RA patient by the long-term high-level local expression of repressor gene
Diameter.But gene therapy is still in infancy at present, there are still many problems.Such as lack ideal carrier, different places
It is main all to need further to grind to whether the gene that carrier generates different immune responses, importing stablize expression etc. in body
Study carefully discussion.In addition, the safety, treatment costs, and ethical issues of gene therapy etc. is also that this research needs what is solved to ask
Topic.
It has been demonstrated that there is certain contact with systemic immunity response and RA in enteric microorganism.Lactic acid bacteria (lactic
Acid bacteria, LAB) pro-inflammatory cytokines level can be reduced under the premise of not influencing regulating cell cerebroysin level, from
And anti-inflammatory effect is played, mitigate RA symptom.Therefore it may be speculated that some make the treatment means that intestinal microecology returns to normal,
While restoring enteron aisle and function of immune system, also certain effect can may be played to RA symptom is mitigated.Research confirms, a kind of
LAB (Bacillus coagulans GBI-30,6086) is likely to become a kind of safe and efficient ancillary drug for mitigating RA symptom
Since cause and onset of disease mechanism is not yet completely understood, though the treatment of RA obtains certain progress, so far still in control
System alleviates asymptomatic stage, and there is no effective treatment or cure.It is therefore a kind of effective new there is an urgent need in the art to develop,
It has no toxic side effect, for treating and preventing the drug of rheumatoid arthritis and its related disease.
Summary of the invention
The present invention is directed to solve at least some of the technical problems in related technologies.For this purpose, of the invention
One purpose is to propose that Clostridium nexile is treating or preventing the purposes in rheumatoid arthritis or its related disease.
In the first aspect of the present invention, the present invention provides the purposes of Clostridium nexile in medicine preparation, the drug is used
In treatment or prevention rheumatoid arthritis or its related disease.Inventors have found that by providing the drug, Neng Gouyou to animal
The symptom of the anti-inflammatory effect of effect performance, joint redness and swelling is effectively improved, and arthritic symptom is substantially reduced, can have
Effect treats or prevents rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
In the second aspect of the present invention, the present invention provides a kind of pharmaceutical compositions.According to an embodiment of the invention, the medicine
Compositions include: Clostridium nexile；And pharmaceutically acceptable auxiliary material.Inventor surprisingly has found, by providing animal
The pharmaceutical composition can obviously inhibit arthritic generation, and joint redness and swelling are obviously declined, and arthritic symptom obviously subtracts
Gently, animal action is flexible, shows that the pharmaceutical composition can effectively treat or prevent rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, described pharmaceutical composition includes 1 × 10-1 when described pharmaceutical composition is in solid-state
×1020The Clostridium nexile of cfu/g, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition include 1 × 10-1 ×
1020The Clostridium nexile of cfu/mL.The effect for inhibiting arthritis to occur and improve arthritic symptom as a result, is obvious, if being
Knot Clostridium content is too low, and the effect for treating or preventing rheumatoid arthritis is undesirable, if Clostridium nexile too high levels, are controlled
It treats or the effect of prevention rheumatoid arthritis is without significantly improving, cause to waste.
According to a preferred embodiment of the present invention, when described pharmaceutical composition is in solid-state, described pharmaceutical composition packet
Containing 1 × 104-1×1015The Clostridium nexile of cfu/g, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition packet
Containing 1 × 104-1×1015The Clostridium nexile of cfu/mL.
According to a further advantageous embodiment of the invention, when described pharmaceutical composition is in solid-state, described pharmaceutical composition
Include 1 × 106-1×1011Cfu/g, the Clostridium nexile, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition
Include 1 × 106-1×1011The Clostridium nexile of cfu/mL.
According to an embodiment of the invention, the pharmaceutically acceptable auxiliary material is selected from carrier, excipient, diluent, profit
At least one of lubrication prescription, wetting agent, emulsifier, suspension stabiliser, preservative, sweetener and fragrance.
According to an embodiment of the invention, the pharmaceutically acceptable auxiliary material is selected from lactose, glucose, sucrose, sorb
Sugar alcohol, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidine
Ketone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, talcum, magnesium stearate and mine
At least one of object oil.
In the third aspect of the present invention, the present invention provides a kind of drugs.According to an embodiment of the invention, the drug packet
It includes: mentioned-above pharmaceutical composition.By providing the drug to animal, it can obviously inhibit arthritic generation, joint hair
Red and swelling is obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, shows that the drug can effectively treat or prevent
Rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the drug is in be selected from granule, capsule, tablet, powder agent, oral solution, suspension
At least one of liquid and emulsion dosage form.It is easy to be administered as a result,.
In the fourth aspect of the present invention, the present invention provides a kind of food.According to an embodiment of the invention, the food packet
It includes: Clostridium nexile；And acceptable auxiliary material in bromatology.Inventors have found that by providing the food to animal, it can be obvious
Inhibit arthritic generation, joint redness and swelling are obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, are shown
The food can effectively treat or prevent rheumatoid arthritis or its related disease.
It should be noted that the type of term " food " used in the present invention is not particularly limited, can for it is any
The food known, including but not limited to dairy produce, biscuit, cake, beverage, health care product etc..
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, the food includes 1 × 10-1 × 10 when the food is in solid-state20Cfu/g's
The Clostridium nexile, when the food is in a liquid state, the food includes 1 × 10-1 × 1020The Clostridium nexile of cfu/mL.
The effect for inhibiting arthritis to occur and improve arthritic symptom as a result, is obvious, if Clostridium nexile content is too low, treats or prevents
The effect of rheumatoid arthritis is undesirable, if Clostridium nexile too high levels, treat or prevent rheumatoid arthritis
Effect without significantly improving, cause to waste.
According to a preferred embodiment of the present invention, when the food is in solid-state, the food includes 1 × 104-1×
1015The Clostridium nexile of cfu/g, when the food is in a liquid state, the food includes 1 × 104-1×1015The institute of cfu/mL
State Clostridium nexile.
According to a further advantageous embodiment of the invention, when the food is in solid-state, the food includes 1 × 106-1
×1011Cfu/g, the Clostridium nexile, when the food is in a liquid state, the food include 1 × 106-1×1011cfu/mL
The Clostridium nexile.
According to an embodiment of the invention, in the bromatology acceptable auxiliary material be selected from carrier, excipient, diluent,
At least one of lubricant, wetting agent, emulsifier, suspension stabiliser, preservative, sweetener and fragrance.
According to an embodiment of the invention, acceptable auxiliary material is selected from lactose, glucose, sucrose, mountain in the bromatology
Pears sugar alcohol, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization cellulose, polyvinyl pyrrole
Alkanone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, talcum, magnesium stearate and
At least one of mineral oil.
According to an embodiment of the invention, the food is in be selected from solid, dairy products, solution product, pulverulent product and suspension
At least one of product dosage form.
In the fifth aspect of the invention, the present invention provides a kind of feeds.According to an embodiment of the invention, the feed packet
It includes: Clostridium nexile.Inventors have found that can obviously inhibit arthritic generation, joint of animal by providing the feed to animal
Rubescent and swelling is obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, shows that the feed can be treated effectively or in advance
Anti- rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
It should be understood that above-mentioned each technical characteristic of the invention and having in below (eg embodiment) within the scope of the present invention
It can be combined with each other between each technical characteristic of body description, to form a new or preferred technical solution.As space is limited, exist
This no longer tires out one by one states.
Detailed description of the invention
Fig. 1 shows according to an embodiment of the present invention, the shadow that microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 fall ill to mouse arthritis
Ring Macroscopic score result；
Fig. 2 shows that according to an embodiment of the present invention microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are to arthritic mice splenocyte body
The influence result of outer proliferation；And
Fig. 3 shows that according to an embodiment of the present invention microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 are to arthritic mice cell factor
Influence result.
Specific embodiment
Present invention will be further explained below with reference to specific examples.It should be understood that these embodiments are merely to illustrate the present invention
Rather than it limits the scope of the invention.In the following examples, the experimental methods for specific conditions are not specified, usually according to conventional strip
Part such as Sambrook et al., molecular cloning: laboratory manual (New York:Cold Spring Harbor Laboratory
Press, 1989) condition described in, or according to " microorganism: laboratory manual " (James Cappuccino and Natalie
Sherman is compiled, Pearson Education publishing house) described in condition, or according to the normal condition proposed by manufacturer.
In the first aspect of the present invention, the present invention provides the purposes of Clostridium nexile in medicine preparation, the drug is used
In treatment or prevention rheumatoid arthritis or its related disease.Inventors have found that by providing the drug, Neng Gouyou to animal
The symptom of the anti-inflammatory effect of effect performance, joint redness and swelling is effectively improved, and arthritic symptom is substantially reduced, can have
Effect treats or prevents rheumatoid arthritis or its related disease.
It should be noted that term " animal " used herein is not particularly limited, there can be enteron aisle to be any
Animal, preferred mammal, more preferable people, Lagomorpha or muroid.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, animal subject forms arthritis model animal, animal pattern intake by modeling
Clostridium nexile DSM 1787, Clostridium nexile A2-232 and Clostridium nexile
SL7/1, can be obviously improved that joint of animal is rubescent and swelling situation, mitigate arthritic symptom.According to an embodiment of the invention,
Respectively through bacterial strain Clostridium nexile DSM 1787, Clostridium nexile A2-232 and Clostridium
Nexile SL7/1 is come the arthritis DBA/1J mouse treated, compared with the control group for not receiving treatment, joint redness and swelling
Obvious to subside, arthritic symptom is substantially reduced.Show that the bacterial strain can be to prevent and treat rheumatoid arthritis as a result,
Or its related disease.
In the second aspect of the present invention, the present invention provides a kind of pharmaceutical compositions.According to an embodiment of the invention, the medicine
Compositions include: Clostridium nexile；And pharmaceutically acceptable auxiliary material.Inventor surprisingly has found, by providing animal
The pharmaceutical composition can obviously inhibit arthritic generation, and joint redness and swelling are obviously declined, and arthritic symptom obviously subtracts
Gently, animal action is flexible, shows that the pharmaceutical composition can effectively treat or prevent rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, described pharmaceutical composition includes 1 × 10-1 when described pharmaceutical composition is in solid-state
×1020The Clostridium nexile of cfu/g, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition include 1 × 10-1 ×
1020The Clostridium nexile of cfu/mL.The effect for inhibiting arthritis to occur and improve arthritic symptom as a result, is obvious, if being
Knot Clostridium content is too low, and the effect for treating or preventing rheumatoid arthritis is undesirable, if Clostridium nexile too high levels, are controlled
It treats or the effect of prevention rheumatoid arthritis is without significantly improving, cause to waste.
According to a preferred embodiment of the present invention, when described pharmaceutical composition is in solid-state, described pharmaceutical composition packet
Containing 1 × 104-1×1015The Clostridium nexile of cfu/g, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition packet
Containing 1 × 104-1×1015The Clostridium nexile of cfu/mL.
According to a further advantageous embodiment of the invention, when described pharmaceutical composition is in solid-state, described pharmaceutical composition
Include 1 × 106-1×1011Cfu/g, the Clostridium nexile, when described pharmaceutical composition is in a liquid state, described pharmaceutical composition
Include 1 × 106-1×1011The Clostridium nexile of cfu/mL.
According to an embodiment of the invention, the pharmaceutically acceptable auxiliary material is selected from carrier, excipient, diluent, profit
At least one of lubrication prescription, wetting agent, emulsifier, suspension stabiliser, preservative, sweetener and fragrance.
According to an embodiment of the invention, the pharmaceutically acceptable auxiliary material is selected from lactose, glucose, sucrose, sorb
Sugar alcohol, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization cellulose, polyvinylpyrrolidine
Ketone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, talcum, magnesium stearate and mine
At least one of object oil.
In the third aspect of the present invention, the present invention provides a kind of drugs.According to an embodiment of the invention, the drug packet
It includes: mentioned-above pharmaceutical composition.By providing the drug to animal, it can obviously inhibit arthritic generation, joint hair
Red and swelling is obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, shows that the drug can effectively treat or prevent
Rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the drug is in be selected from granule, capsule, tablet, powder agent, oral solution, suspension
At least one of liquid and emulsion dosage form.It is easy to be administered as a result,.
In the fourth aspect of the present invention, the present invention provides a kind of food.According to an embodiment of the invention, the food packet
It includes: Clostridium nexile；And acceptable auxiliary material in bromatology.Inventors have found that by providing the food to animal, it can be obvious
Inhibit arthritic generation, joint redness and swelling are obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, are shown
The food can effectively treat or prevent rheumatoid arthritis or its related disease.
It should be noted that the type of term " food " used in the present invention is not particularly limited, it can be any public affairs
The food known, including but not limited to dairy produce, biscuit, cake, beverage, health care product etc..
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, the food includes 1 × 10-1 × 10 when the food is in solid-state20Cfu/g's
The Clostridium nexile, when the food is in a liquid state, the food includes 1 × 10-1 × 1020The Clostridium nexile of cfu/mL.
The effect for inhibiting arthritis to occur and improve arthritic symptom as a result, is obvious, if Clostridium nexile content is too low, treats or prevents
The effect of rheumatoid arthritis is undesirable, if Clostridium nexile too high levels, treat or prevent rheumatoid arthritis
Effect without significantly improving, cause to waste.
According to a preferred embodiment of the present invention, when the food is in solid-state, the food includes 1 × 104-1×
1015The Clostridium nexile of cfu/g, when the food is in a liquid state, the food includes 1 × 104-1×1015The institute of cfu/mL
State Clostridium nexile.
According to a further advantageous embodiment of the invention, when the food is in solid-state, the food includes 1 × 106-1
×1011Cfu/g, the Clostridium nexile, when the food is in a liquid state, the food include 1 × 106-1×1011cfu/mL
The Clostridium nexile.
According to an embodiment of the invention, in the bromatology acceptable auxiliary material be selected from carrier, excipient, diluent,
At least one of lubricant, wetting agent, emulsifier, suspension stabiliser, preservative, sweetener and fragrance.
According to an embodiment of the invention, acceptable auxiliary material is selected from lactose, glucose, sucrose, mountain in the bromatology
Pears sugar alcohol, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization cellulose, polyvinyl pyrrole
Alkanone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, nipasol, talcum, magnesium stearate and
At least one of mineral oil.
According to an embodiment of the invention, the food is in be selected from solid, dairy products, solution product, pulverulent product and suspension
At least one of product dosage form.
In the fifth aspect of the invention, the present invention provides a kind of feeds.According to an embodiment of the invention, the feed packet
It includes: Clostridium nexile.Inventors have found that can obviously inhibit arthritic generation, joint of animal by providing the feed to animal
Rubescent and swelling is obviously declined, and arthritic symptom is substantially reduced, and animal action is flexible, shows that the feed can be treated effectively or in advance
Anti- rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile is Clostridium nexile.Thereby, it is possible to effectively play
The effect for the treatment of or preventing rheumatoid arthritis or its related disease.
According to an embodiment of the invention, the Clostridium nexile be selected from Clostridium nexile DSM 1787,
At least one of Clostridium nexile A2-232 and Clostridium nexile SL7/1.Treatment or pre- as a result,
The effect of anti-rheumatoid arthritis or its related disease is preferable.
According to an embodiment of the invention, the feed includes 1 × 10-1 × 10 when the feed is in solid-state20Cfu/g's
The Clostridium nexile, when the feed is in a liquid state, the feed includes 1 × 10-1 × 1020The Clostridium nexile of cfu/mL.
The effect for inhibiting arthritis to occur and improve arthritic symptom as a result, is obvious, if Clostridium nexile content is too low, treats or prevents
The effect of rheumatoid arthritis is undesirable, if Clostridium nexile too high levels, treat or prevent rheumatoid arthritis
Effect without significantly improving, cause to waste.
According to a preferred embodiment of the present invention, when the feed is in solid-state, the feed includes 1 × 104-1×
1015The Clostridium nexile of cfu/g, when the feed is in a liquid state, the feed includes 1 × 104-1×1015The institute of cfu/mL
State Clostridium nexile.
According to a further advantageous embodiment of the invention, when the feed is in solid-state, the feed includes 1 × 106-1
×1011Cfu/g, the Clostridium nexile, when the feed is in a liquid state, the feed include 1 × 106-1×1011cfu/mL
The Clostridium nexile.
Embodiment 1 determines the beneficial bacterium for treating or preventing rheumatoid arthritis
1.1 sample collections and DNA are extracted
Collecting the excrement, tartar and saliva sample of 212 volunteers altogether from BJ Union Hospital, sample message is shown in Table 1,
Wherein, it is divided into training group and test group.Training group includes 157 volunteers, wherein 77 are the RA case that do not treated, 80
A is healthy person (control).In test group, wherein 34 volunteers' formation 17 " case-health " are right, wherein there is 8 pairs to have blood relationship
In addition relationship does not have genetic connection for 9 pairs；Other 21 volunteers are DMARD (disease-modifying
Antirheumatic drugs) treatment RA case.
Acquisition fecal specimens after refrigeration transportation and be quickly transferred to -80 DEG C preservation, carry out DNA extraction (refer to Qin, J.et
al.A metagenome-wide association study of gut microbiota in type
2diabetes.Nature 490,55–60(2012)).When acquiring tartar sample, 3 μ l are scraped from dental surface using medical calm
Tartar, be transferred to 200 μ l 1x lysis buffers (10mM Tris, 1mM EDTA, 0.5% polysorbas20,200 μ g/ml protease
K it in), cultivates at 55 DEG C 2 hours, is then cultivated 10 minutes at 95 DEG C, terminate cracking reaction, finally saved in -80 DEG C.Acquire saliva
When liquid sample, take 100 μ l samples into the collecting pipe for containing 100 μ l 2x lysis buffers, meanwhile, scrape posterior phraynx surface sample
It adds in the pipe, subsequent cleavage step is identical as tartar sample, equally saves in -80 DEG C.Tartar sample and saliva sample are through cold
Freeze transport to BGI-Shenzhen, carries out DNA extraction referring to fecal specimens.
When volunteer is admitted to hospital for the first time, phenotypic information is collected according to standardization program.The excrement sample of 21 DMARD treatment cases
Product are only contained among 212 fecal specimens for constructing enteric microorganism gene set, are no longer analyzed herein.Originally it grinds
Study carefully to obtain BJ Union Hospital and the approval of BGI-Shenzhen's Institutional Review Board.
1 sample message of table
1.2 macro gene order-checkings and assembling
Sequencing library is constructed using extracted DNA sample, two-way (Paired- is carried out in Illumina microarray dataset
End) macro gene order-checking (Insert Fragment 350bp reads long 100bp).The data generated to sequencing are filtered (quality-
Controlled, removal adapter polluted sequence go low quality sequence and remove host genome polluted sequence), and utilize
SOAPdenovo software (v2.04) carries out accent assembling.
The average host genome pollution of excrement, tartar and saliva sample is 0.37%, 5.55% and 40.85% respectively.
The building of 1.3 gene sets
For assembled assembling segment (contigs), predictive genes are carried out using GeneMark software (v2.7d), are connect
Using BLAT software carry out de-redundancy (alignment similarity (identity) 95% or more, the coverage (overlap) of comparison
90% or more, without notch (gaps)), for 212 fecal specimens (treating sample including 21 DMARD), obtain
Nonredundancy gene set comprising 3,800,011 genes；For 203 buccal samples (including 105 tartar samples and 98 salivas
Liquid sample), obtain the nonredundancy gene set comprising 3,234,997 genes.Using BLAT software by fecal specimens gene set
The published enteric microorganism for including more than 430 ten thousand genes is further added to reference to (alignment similarity exists in gene set
95% or more, coverage is compared 90% or more, with reference to above-mentioned document Qin, J.et al.2012), it has finally obtained comprising 590
The new gene collection of more ten thousand genes.
High quality sequencing fragment (reads) is compared with enteron aisle or oral cavity with reference to gene set, to obtain gene
Relative abundance (refers to above-mentioned document Qin, J.et al.2012).
1.4 species taxonomies annotation is calculated with abundance
By being compared with IMG (v400) database, species taxonomy is carried out to the gene of prediction and (refers to above-mentioned document
Qin, J.et al.2012), respectively obtaining a horizontal species taxonomy, (alignment similarity compares coverage and exists 65% or more
70% or more) the horizontal species taxonomy (alignment similarity of the species taxonomy (alignment similarity is 85% or more) and kind for, belonging to horizontal
95% or more).Using the relative abundance of gene calculate the species relative abundance (refer to above-mentioned document Qin,
J.etal.2012 it), and with rank sum test (Wilcoxon rank-sum test) carries out statistical check (p < 0.05), determines disease
Example with compare between relative abundance there are the species of significant difference.
1.5 macro genome association analyses
It is (every in 3,110,085 genes by comparing case and the fecal microorganism gene set (microbiome) that compares
A gene all at least appears in 6 samples, sample n=157, treats case without 21 DMARD described in table 1) in, discovery
The relative abundance of 83,858 genes has significant difference (p < 0.01, rank sum test, FDR=0.3285), these genes are
Marker gene.According to the relative abundance difference of these marker gene in the sample, further clusters, obtain the macro genome of excrement
(Group, MLG, one MLG of Metagenomic Linkage are similar to a species to linkage group, and clustering method refers to above-mentioned text
Offer Qin, J.et al.2012).Same method, from the 2 of tartar, 247,835 genes, (each gene at least appears in 6
In a sample, sample n=105) in, 209,820 marker gene (p < 0.01, rank sum test, FDR=0.072) are filtered out, are gathered
Class obtains the MLG of tartar.From the 2 of saliva, 404,726 genes, (each gene is at least appeared in 6 samples, sample n
=98) in, 206,399 marker gene (p < 0.01, rank sum test, FDR=0.088) are filtered out, clusters, obtains saliva MLG.
In addition, from 1,538,688 gene, (each gene at least goes out by comparing DMARD pretherapy and post-treatment fecal microorganism gene
In present 6 samples, sample n=64) in, filter out 86158 marker gene (p < 0.05, paired Wilcoxon rank-
Sum test, FDR=0.912), it clusters into the excrement MLGs of DMARD treatment case.
According to the classification and relative abundance of MLGs constitutivegene, MLGs species taxonomy and building MLGs relative abundance spectrum are carried out
(referring to above-mentioned document Qin, J.et al.2012).To be categorized into the level of kind, the gene for needing to meet in MLGs 90% can
To compare onto the genome of the species (alignment similarity compares coverage 70% or more 95% or more).To classification
It is horizontal to belonging to, then need in MLGs 80% gene, the similarity either in DNA sequence dna or protein sequence, with the category
80% will be higher than.According to Kendall ' s correlation (the regardless of case-control between all samples abundance
Status), MLGs can further be clustered.Enteron aisle MLG, saliva MLG, tartar MLG MLG related to DMARD treatment
Species taxonomy result be shown in Table 2, table 3, table 4, table 5 respectively.
The species taxonomy information of 2 enteron aisle MLG of table
The species taxonomy information of 3 saliva MLG of table
The species taxonomy information of 4 tartar MLG of table
The species taxonomy information of table 5DMARD treatment correlation MLG
2 zoopery of embodiment verifying
The beneficial bacterium for the treatment of or prevention rheumatoid arthritis is determined to verify embodiment 1 in table 2, table 3, table 4, table 5,
Inventor carries out zoopery to each strain, utilizes its effect of host strains obtained by the strain.
Experimental method
1. modeling and administration
6~8 week old SPF (Specific pathogen free) grade male DBA/1J mouse, is purchased from the Chinese Academy of Sciences
Extra large Experimental Animal Center, raising (are tested in IVC (individual ventilated cage) mouse cage system purchased from Suzhou Feng Shi
Animal facilities Co., Ltd), 22~24 DEG C of indoor holding temperature, humidity 40%~60%, daily illumination 12h, ad lib and
Drinking-water.Adaptive feeding is randomly divided into 5 groups of (model control group, 1 group of microbial inoculum, 2 groups of microbial inoculum, 3 groups of microbial inoculums, normal control after 2 weeks
Group), every group 12.Clostridium nexile DSM 1787 (microbial inoculum 1) is purchased from DSMZ (Leibniz-Institut
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH)；Clostridium
Nexile A2-232 (microbial inoculum 2) and Clostridium nexile SL7/1 (microbial inoculum 3) derive from Luo Weite research institute of Britain
Enteric microorganism and immunization department (Division of Gut Microbiology and Immunology, Rowett
Research Institute).In kitchen meat carbohydrate culture solution (DSMZ Medium110), 37 DEG C of Anaerobic culturel 24-
48h starts to test after 16S rDNA sequencing identification is errorless.Bacterial strain information is shown in Table 6.
6 bacterial strain information of table
| Number | Strain name |
| Microbial inoculum 1 | Clostridium nexile DSM 1787 |
| Microbial inoculum 2 | Clostridium nexile A2-232 |
| Microbial inoculum 3 | Clostridium nexile SL7/1 |
With reference to method (S.Yoshino, E.Sasatomi, M.Ohsawa, the Bacterial of S.Yoshino
lipopolysaccharide acts as an adjuvant to induce autoimmune arthritis in
Mice, 2000) modeling method, in brief:
From experiment the 1st day, 1 group of microbial inoculum (microbial inoculum 1+CIA/LPS), 2 groups of microbial inoculum (microbial inoculum 2+CIA/LPS), 3 groups of microbial inoculum
(microbial inoculum 3+CIA/LPS) is respectively with 500 μ l/50g.BW dosage, stomach-filling bacterium 1, bacterium 2,3 fresh medium (10 of bacterium9-1010cfu/
Ml), model control group (M+CIA/LPS) and Normal group (M+AA+PBS) the difference isometric aseptic culture fluid of stomach-filling, every other day
Administration 28 days.On day 1, the 21st day, lipopolysaccharides (LPS) is combined to induce 3 model group (microbial inoculums 1 using II Collagen Type VI (CIA)
3 groups of group, 2 groups of microbial inoculum and microbial inoculum) and model control group mouse arthritis generation.Concrete operations are as follows: by 100mg II Collagen Type VI
Albumen (being derived from calf articular cartilage, Funakoshi Co) is dissolved in 100ml 5mM acetic acid (AA), and 4 DEG C are stirred overnight, intraperitoneal injection
Mouse.The 1 μ g of lipopolysaccharides (Shanghai Vaccine and Serum Institute) for then taking E.coli 011:B4, is dissolved in 0.1ml phosphate buffer
(PBS), equally through intraperitoneal injection.Normal group is in 5mM acetic acid and PBS buffer solution abdomen of the same time point through same volume
Chamber injection.Observation mouse foot claw-like state daily, weekly scores to arthritis index.In experiment start after 35 days, every group with
Machine chooses 6 execution, and spleen cell is taken to carry out subsequent experimental.Remaining mouse continues to observe course of arthritis progress and in reality
50 days cervical dislocations are put to death after testing beginning.
2. arthritis evaluations
Arthritic severity is carried out according to the increase and periarticular tissue edema situation of erythema using naked eyes
Macroscopic score obtains arthritis index, and specific standards of grading are described as follows: 0: without arthritic sign；1:1 arthroncus
And/or it is rubescent；2:2 arthroncus and/or rubescent；3: greater than 2 arthroncus and/or rubescent；4: entire foot pawl occurs tight
Weight arthritis.Every mouse arthritis index is the sum of every 4 pawl score of animal.
3. the influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to Collagen-Induced Arthritis mouse boosting cell in-vitro multiplication
It is each to randomly select model group (3 groups of 1 group of microbial inoculum, 2 groups of microbial inoculum and microbial inoculum), model control group and every group of Normal group
6 mouse, conventional separating Morr. cell.With reference to the method for Zhao Xiaohui etc., (Sailongbone extracts lure ox II Collagen Type VI for subsequent operation
The therapeutic effect and Mechanism Study for the mouse arthritis led, Zhao Xiaohui, Yue Huilan, Mei Lijuan, Shao Zan, Tao Yanduo, 2008 years 5
Month): cell concentration is tuned into 4 × 10 with the RPMI 1640 culture medium containing 10% calf serum6cell/ml.It is every in 96 orifice plates
100 μ l cell suspensions, 100 μ l collagen antigens are added in hole.Cell is in containing 5%CO237 DEG C of incubators in cultivate, culture knot
25 μ l are added in the every hole 8h before beam3H- thymidylic acid.It continues to culture until the end of the experiment.Cell is received with cell collector
Collection is on glass fibre membrane, being added after scintillation solution in reading in cell DNA on β calculating instrument3H- thymidylic acid amount, with every
Minute umber of pulse (counts per minute, cpm) indicates cell proliferative conditions.
4. the influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to arthritic mice inflammatory cytokine
Conventional method separating Morr. cell, cell concentration is tuned into 4 with the RPMI 1640 culture medium containing 10% calf serum ×
106Cell/ml is inoculated in 24 hole tissue culturing plates with the hole splenocyte suspension 1ml/, wherein glutamine containing 1mM, 100U/ml
Penicillin, 100mg/ml streptomysin, 5 × 10-5M 2 mercapto ethanol and 1% heat inactivation autoserum.After 48h, supernatant is collected
It is saved in -70 DEG C, detects wherein cell factor IL- using ELISA kit (being purchased from the enzyme-linked Biotechnology Co., Ltd in Shanghai)
12, IFN-γ, TNF-α and IL-10 are horizontal.
Experimental result
1. the influence that microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 fall ill to mouse arthritis.
Microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 the results are shown in Table 7 and Fig. 1 to the Macroscopic score for the influence that mouse arthritis is fallen ill.By reality
After result is tested it is found that microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 be administered 4 weeks, model control group is compared, CIA mouse joint can be obviously inhibited
Scorching generation, mouse foot swelling are obviously declined, and arthritic symptom is substantially reduced, and mouse action is more flexible.
The influence result (every group of 6 mouse) that 7 microbial inoculum 1 of table, microbial inoculum 2 and microbial inoculum 3 fall ill to mouse arthritis
2. the influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to arthritic mice splenocyte in-vitro multiplication
The influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to arthritic mice splenocyte in-vitro multiplication the results are shown in Table 8 and Fig. 2,
In, numerical value is not significant (p > 0.05) through Tukey ' s Test detection difference between indicating two groups with same letter mark.It is tied by test
Fruit is it is found that by gavaging microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3, and in the case where adding antigen, arthritic mice splenocyte is in vitro through antigen
Post-stimulatory breeder reaction is substantially reduced compared with model control group, and under conditions of antigen is not added, each model group is also shown
Different degrees of Spleen cell proliferation inhibiting effect.
The influence (every group of 6 mouse) of 8 microbial inoculum 1 of table, microbial inoculum 2 and microbial inoculum 3 to arthritic mice splenocyte in-vitro multiplication
3. the influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to arthritic mice cell factor
The influence of microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 to arthritic mice cell factor the results are shown in Table 9 and Fig. 3, wherein identical
Numerical value is not significant (p > 0.05) through Tukey ' s Test detection difference between letter indicates two groups.According to the experimental results, lead to
ELISA detection is crossed it can be found that 3 model group mouse cell suppression inflammation factor IL-10 secretions significantly subtract compared with Normal group
Few (p < 0.05), inflammatory factor IL-12, TNF-α and IFN-γ secretion significantly increase (p < 0.05)；Compared with model control group,
Model group mouse cell IL-10 secretion significantly increases (p < 0.05), IL-12, IFN-γ, TNF-α secretion substantially reduce (p <
0.05) without significant difference (p > 0.05), and between 3 model groups.Illustrate that microbial inoculum 1, microbial inoculum 2 and 3 stomach-filling of microbial inoculum are able to suppress spleen
The secretion of inflammatory factor IL-12, IFN-γ, TNF-α in cells and supernatant, and improve the secretion for pressing down scorching factor IL-10, display
Microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 have obvious inhibiting effect to arthritic mice cell immunity of spleen hyperfunction.
The influence (every group of 6 mouse) of 9 microbial inoculum 1 of table, microbial inoculum 2 and microbial inoculum 3 to arthritic mice cell factor
Conclusion
The above results show that on CIA mouse model of rheumatoid arthritis, microbial inoculum 1, microbial inoculum 2 and microbial inoculum 3 can be obvious
Inhibit the morbidity of mouse arthritis, mitigates the related symptoms of CIA mouse, show preferable anti-inflammatory effect.
In the description of this specification, reference term " one embodiment ", " some embodiments ", " example ", " specifically show
The description of example " or " some examples " etc. means specific features, structure, material or spy described in conjunction with this embodiment or example
Point is included at least one embodiment or example of the invention.In the present specification, schematic expression of the above terms are not
It must be directed to identical embodiment or example.Moreover, particular features, structures, materials, or characteristics described can be in office
It can be combined in any suitable manner in one or more embodiment or examples.In addition, without conflicting with each other, the skill of this field
Art personnel can tie the feature of different embodiments or examples described in this specification and different embodiments or examples
It closes and combines.
Although the embodiments of the present invention has been shown and described above, it is to be understood that above-described embodiment is example
Property, it is not considered as limiting the invention, those skilled in the art within the scope of the invention can be to above-mentioned
Embodiment is changed, modifies, replacement and variant.
Claims (13)
1. the purposes of Clostridium nexile in medicine preparation, the drug is used to treat or prevent rheumatoid arthritis,
The Clostridium nexile is Clostridium nexile.
2. purposes according to claim 1, which is characterized in that the Clostridium nexile is selected from Clostridium nexile
At least one of DSM 1787, Clostridium nexile A2-232 and Clostridium nexile SL7/1.
3. a kind of for treating or preventing the pharmaceutical composition of rheumatoid arthritis characterized by comprising
Clostridium nexile；And
Pharmaceutically acceptable auxiliary material,
The Clostridium nexile is Clostridium nexile.
4. pharmaceutical composition according to claim 3, which is characterized in that the Clostridium nexile is selected from Clostridium
At least one in nexile DSM 1787, Clostridium nexile A2-232 and Clostridium nexile SL7/1
Kind.
5. pharmaceutical composition according to claim 3, which is characterized in that described when described pharmaceutical composition is in solid-state
Pharmaceutical composition includes 1 × 10-1 × 1020The Clostridium nexile of cfu/g,
When described pharmaceutical composition is in a liquid state, described pharmaceutical composition includes 1 × 10-1 × 1020The tying shuttle of cfu/mL
Bacterium.
6. pharmaceutical composition according to claim 5, which is characterized in that described when described pharmaceutical composition is in solid-state
Pharmaceutical composition includes 1 × 104-1×1015The Clostridium nexile of cfu/g,
When described pharmaceutical composition is in a liquid state, described pharmaceutical composition includes 1 × 104-1×1015The tying of cfu/mL
Clostridium.
7. pharmaceutical composition according to claim 5, which is characterized in that described when described pharmaceutical composition is in solid-state
Pharmaceutical composition includes 1 × 106-1×1011The Clostridium nexile of cfu/g,
When described pharmaceutical composition is in a liquid state, described pharmaceutical composition includes 1 × 106-1×1011The tying of cfu/mL
Clostridium.
8. pharmaceutical composition according to claim 3, which is characterized in that the pharmaceutically acceptable auxiliary material is selected from load
At least one in body, diluent, lubricant, wetting agent, emulsifier, suspension stabiliser, preservative, sweetener and fragrance
Kind.
9. pharmaceutical composition according to claim 8, which is characterized in that the pharmaceutically acceptable auxiliary material is selected from cream
Sugar, glucose, sucrose, D-sorbite, mannose, starch, Arabic gum, calcium phosphate, alginates, gelatin, calcium silicates, fine crystallization
Cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methyl hydroxybenzoate, hydroxybenzoic acid third
At least one of ester, talcum, magnesium stearate and mineral oil.
10. a kind of drug characterized by comprising
Pharmaceutical composition described in any one of claim 3-9.
11. drug according to claim 10, which is characterized in that the drug is in be selected from granule, capsule, tablet, powder
At least one of last agent, oral solution, suspension and emulsion dosage form.
12. a kind of for treating or preventing the feed of rheumatoid arthritis characterized by comprising Clostridium nexile,
The Clostridium nexile is Clostridium nexile.
13. feed according to claim 12, which is characterized in that the Clostridium nexile is selected from Clostridium
At least one in nexile DSM 1787, Clostridium nexile A2-232 and Clostridium nexile SL7/1
Kind.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410524063.7A CN104546937B (en) | 2014-09-30 | 2014-09-30 | Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease |
| HK15110196.4A HK1209367A1 (en) | 2014-09-30 | 2015-10-16 | Use of clostridium nexile in the treatment or prevention of rheumatoid arthritis or related diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410524063.7A CN104546937B (en) | 2014-09-30 | 2014-09-30 | Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104546937A CN104546937A (en) | 2015-04-29 |
| CN104546937B true CN104546937B (en) | 2019-02-01 |
Family
ID=53064709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410524063.7A Active CN104546937B (en) | 2014-09-30 | 2014-09-30 | Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN104546937B (en) |
| HK (1) | HK1209367A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019178494A1 (en) * | 2018-03-15 | 2019-09-19 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and inflammation using tyzzerella nexilis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101310730A (en) * | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | Use of clostridium butyricum for preparing microbiological preparation for preventing and curing atrophic arthritis, ankylosing spondylitis |
| CN101496819A (en) * | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | Eubacterium, Clostridium preparation and use thereof |
| CN102670663A (en) * | 2008-01-31 | 2012-09-19 | 青岛东海药业有限公司 | Clostridium preparation and application thereof |
| CN103561752A (en) * | 2011-03-09 | 2014-02-05 | 明尼苏达大学评议会 | Compositions and methods for transplantation of colon microbiota |
| CN103717233A (en) * | 2011-03-18 | 2014-04-09 | 亚历山大·爱德华多·诺威尔 | Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
-
2014
- 2014-09-30 CN CN201410524063.7A patent/CN104546937B/en active Active
-
2015
- 2015-10-16 HK HK15110196.4A patent/HK1209367A1/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101310730A (en) * | 2007-05-27 | 2008-11-26 | 青岛东海药业有限公司 | Use of clostridium butyricum for preparing microbiological preparation for preventing and curing atrophic arthritis, ankylosing spondylitis |
| CN101496819A (en) * | 2008-01-31 | 2009-08-05 | 青岛东海药业有限公司 | Eubacterium, Clostridium preparation and use thereof |
| CN102670663A (en) * | 2008-01-31 | 2012-09-19 | 青岛东海药业有限公司 | Clostridium preparation and application thereof |
| CN103561752A (en) * | 2011-03-09 | 2014-02-05 | 明尼苏达大学评议会 | Compositions and methods for transplantation of colon microbiota |
| CN103717233A (en) * | 2011-03-18 | 2014-04-09 | 亚历山大·爱德华多·诺威尔 | Immunogenic composition for immune system modulation and use thereof, method for treating and preventing diseases, method for inducing cell regeneration and method for restoring immune response |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1209367A1 (en) | 2016-04-01 |
| CN104546937A (en) | 2015-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104546934B (en) | Excrement pair bacteroid is treating or preventing the application in rheumatoid arthritis or its related disease | |
| CN104546932A (en) | Application of bacteroides ovatus in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546940A (en) | Application of common bacteroides in treatment or prevention of rheumatoid arthritis or related diseases thereof | |
| CN104546933A (en) | Application of bacteroides caccae in treatment or prevention of rheumatoid arthritis or related diseases thereof | |
| CN104546942A (en) | Application of bacteroides dorei in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546935A (en) | Application of bacteroides thetaiotaomicron in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN107847529B (en) | Compositions comprising bacterial strains | |
| Ochoa-Reparaz et al. | A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease | |
| CN102115721B (en) | Lactobacillus isolated strains with anti-inflammatory activity and use thereof | |
| CN104546930B (en) | Haemophilus parainfluenzae is treating or preventing the application in rheumatoid arthritis or its related disease | |
| US11911423B2 (en) | Bifidobacterium lactis BL-99 and application thereof | |
| Wang et al. | Protective effect of Lactobacillus plantarum P8 on growth performance, intestinal health, and microbiota in Eimeria-infected broilers | |
| Fan et al. | The prophylactic effects of different Lactobacilli on collagen-induced arthritis in rats | |
| CN104546938B (en) | Extremely huge Megamonas is treating or preventing the application in rheumatoid arthritis | |
| CN104546945A (en) | Application of bifidobacterium bifidum in treating or preventing rheumatoid arthritis or related diseases thereof | |
| CN104546947B (en) | Lactobacillus crispatus is treating or preventing the application in rheumatoid arthritis | |
| CN104546944B (en) | Lactococcus lactis is treating or preventing the application in rheumatoid arthritis or its related disease | |
| Duan et al. | Oral administration of Lactobacillus plantarum JC7 alleviates OVA-induced murine food allergy through immunoregulation and restoring disordered intestinal microbiota | |
| CN104546939B (en) | Muddiness wears Alister bacterium and is treating or preventing the application in rheumatoid arthritis | |
| EP3932416A2 (en) | Composition for improving, preventing, or treating bone diseases or metabolic diseases, including novel lactobacillus sakei cvl-001 strain and culture medium thereof | |
| CN104546937B (en) | Clostridium nexile is treating or preventing the application in rheumatoid arthritis or its related disease | |
| CN104546936B (en) | Fleck melaninogenicus is treating or preventing the application in rheumatoid arthritis | |
| CN104546943B (en) | Sharpe other style bacillus is treating or preventing the application in rheumatoid arthritis or its related disease | |
| CN104546941B (en) | Actinomyces naeslundii is treating or preventing the application in rheumatoid arthritis or its related disease | |
| CN104546951B (en) | Regular fecal bacteria is treating or preventing the application in rheumatoid arthritis or its related disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1209367 Country of ref document: HK |
|
| CB02 | Change of applicant information |
Address after: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant after: BGI-Shenzhen Co., Ltd. Applicant after: Shenzhen Huada Academy of life science Address before: 518083 11F-3, Beishan industrial complex, 146 Beishan Road, Yantian District, Shenzhen, Guangdong Applicant before: BGI-Shenzhen Co., Ltd. Applicant before: BGI-Shenzhen |
|
| CB02 | Change of applicant information | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |